Drainage device

Abstract

The invention relates to the technical field of drainage, and provides a drainage device which can reduce the probability that a drainage tube is blocked. The drainage device comprises a drainage tube and a slow release assembly, the drainage tube is provided with an in-vivo end and an in-vitro end, the in-vivo end is provided with a drainage opening, and the in-vitro end is provided with a connecting opening; the slow-release assembly comprises a slow-release part, the slow-release part is provided with a slow-release cavity used for containing anticoagulant medicine, and the slow-release cavity is located in the drainage tube and is close to the inner end of the body in the extending direction of the drainage tube so as to release the anticoagulant medicine into the drainage tube.

Description

TECHNICAL FIELD

[0001] The present application relates to the technical field of drainage, in particular to a drainage device. BACKGROUND

[0002] After cardiac surgery, a drainage tube is placed in the pericardium or chest cavity of the patient to drain blood, exudate and the like, which is an essential operation after surgery. At present, clinical practice attaches great importance to the patency of the drainage tube to accurately assess postoperative bleeding and thus timely clinical disposal. However, in the current actual related technology, there is a certain probability of accidental risk of blockage of the drainage tube during application. SUMMARY

[0003] In order to solve the above technical problems, the present application provides a drainage device which can reduce the probability of blockage of the drainage tube.

[0004] The present application provides a drainage device, which comprises a drainage tube and a slow-release assembly. The drainage tube has an in-vivo end and an in-vitro end. The in-vivo end is provided with a drainage port, and the in-vitro end is provided with a connecting port. The slow-release assembly comprises a slow-release member. The slow-release member has a slow-release cavity for accommodating an anticoagulant. The slow-release cavity is located in the drainage tube and is arranged close to the in-vivo end in the extension direction of the drainage tube, so as to release the anticoagulant into the drainage tube.

[0005] The in-vivo end of the drainage tube is placed in the body during use to collect liquid through the drainage port. The in-vitro end of the drainage tube is placed outside during use to guide the drained liquid to a collection container through the connecting port. The in-vivo end is the source of the drainage tube and is also the most likely location for thrombus formation. The slow-release cavity is arranged close to the in-vivo end to provide anticoagulants as soon as the drainage liquid enters the most initial end of the drainage tube, thereby maximally inhibiting the nucleation, growth and spread of thrombus from the source. Since the high coagulability problem is solved at the drainage port, the fluid in the middle and rear sections (close to the in-vitro end) of the drainage tube can always remain in a low coagulability state, thereby ensuring the patency of the entire section of the tube from the in-vivo end to the in-vitro end. Compared with the way of maintaining patency by crushing thrombus by squeezing the drainage tube in the actual related technology, the drainage device provided by the present application comprises a slow-release member, and the slow-release cavity of the slow-release member can release the anticoagulant into the position close to the in-vivo end of the drainage tube, thereby changing from passive post-blocking treatment to active source prevention, reducing the probability of blockage of the drainage tube, reducing the effort and time of medical staff, and avoiding misjudgment of the amount of postoperative bleeding, thereby missing the effective opportunity of timely thoracotomy for hemostasis.

[0006] In some implementations, the cavity wall of the slow-release cavity is provided with a microneedle structure, and the slow-release cavity releases the anticoagulant into the drainage tube through the microneedle structure.

[0007] In some implementations, the slow-release member is a slow-release tube, the slow-release tube includes a first section and a second section, the first section is located in the drainage tube, and one end of the first section towards the in-vivo end is a blind end, a slow-release cavity is formed in the first section, the second section is located outside the drainage tube, and the slow-release assembly further includes a pump member, the pump member is connected with the second section, and is used for pumping the anticoagulant into the slow-release cavity.

[0008] In some implementations, the drainage device further includes a pressure monitoring module and an alarm, the pressure monitoring module is configured to monitor the pressure in the slow-release cavity, and the alarm is in communication connection with the pressure monitoring module, and is configured to trigger an alarm when the pressure value monitored by the pressure monitoring module exceeds a target range.

[0009] In some implementations, the first section includes a first part and a second part, the radial dimension of the first part is greater than the radial dimension of the second part, and the slow-release cavity is formed in the first part.

[0010] In some implementations, the first section is coaxially arranged with the drainage tube.

[0011] In some implementations, the first section is arranged immediately adjacent to the inner wall of the drainage tube.

[0012] In some implementations, the ratio between the radial dimension of the drainage tube and the radial dimension of the slow-release tube is greater than 12 and less than 28.

[0013] In some implementations, the in-vivo end is provided with a buffer pad.

[0014] In some implementations, the drainage tube is provided with a scale on the tube wall. BRIEF DESCRIPTION OF DRAWINGS

[0015] The drawings incorporated into the specification and constituting a part of the specification show embodiments consistent with the present application and, together with the specification, serve to explain the principles of the present application.

[0016] In order to more clearly illustrate the technical solutions in the embodiments of the present application or the prior art, the drawings needed to be used in the embodiments or the prior art description will be briefly introduced as follows. Obviously, for those skilled in the art, other drawings can also be obtained from these drawings without any creative labor.

[0017] Figure 1 One of the structural schematic diagrams of the drainage device provided by the embodiments of the present application; Figure 2 For Figure 1 The enlarged view of A in FIG. 4; Figure 3 The second structural schematic diagram of the drainage device provided by the embodiments of the present application.

[0018] Explanation of reference signs: 1 - drainage tube; 11 - in vivo end; 12 - in vitro end; 2 - sustained release assembly; 21 - sustained release member; 211 - sustained release cavity; 212 - first section; 2121 - first part; 2122 - second part; 213 - second section; 3 - pump member; 4 - three-way valve; 5 - pressure monitoring module; 6 - alarm; 7 - support. DETAILED DESCRIPTION

[0019] In order to more clearly understand the above objectives, features and advantages of the present application, the solutions of the present application will be further described below. It should be noted that the embodiments of the present application and the features in the embodiments can be combined with each other without conflict.

[0020] In the following description, a large number of specific details are set forth in order to facilitate a thorough understanding of the present application, but the present application can also be implemented in other different manners from those described herein; obviously, the embodiments in the specification are only a part of the embodiments of the present application, and not all the embodiments.

[0021] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the present application belongs; the terms used herein are only for the purpose of describing specific embodiments, and are not intended to limit the present application; the terms "include" and "have" and any variations thereof in the specification and claims of the present application and the above description of drawings are intended to cover non-exclusive inclusion.

[0022] In the description of the embodiments of the present application, the technical terms "first", "second", "third" and the like are only used to distinguish different objects, and cannot be understood as indicating or implying relative importance or implicitly indicating the number, specific order or primary and secondary relationship of the indicated technical features. In the description of the embodiments of the present application, the meaning of "a plurality of" is two or more, unless otherwise explicitly and specifically limited.

[0023] Reference herein to "an embodiment" means that a particular feature, structure, or characteristic described in connection with the embodiment can be included in at least one embodiment of the present application. The appearance of the phrase in various places in the specification does not necessarily all refer to the same embodiment, nor is it necessarily independent or alternative embodiments to each other. It is explicitly and implicitly understood by those skilled in the art that the embodiments described herein can be combined with other embodiments.

[0024] In the description of the embodiments of the present application, the term "and / or" is only a description of the association relationship of the associated objects, which means that there can be three relationships, for example, A and / or B, which can represent the three cases of A alone, A and B together, and B alone. In addition, the character " / " in this paper generally represents the "or" relationship between the front and rear associated objects.

[0025] In the description of the embodiments of this application, the technical terms "length", "width", "thickness", "upper", "lower", "front", "rear", "left", "right", "vertical", "horizontal", "top", "bottom", "inner", "outer", "circumferential", etc., indicate the orientation or positional relationship based on the orientation or positional relationship shown in the accompanying drawings. They are only for the convenience of describing the embodiments of this application and simplifying the description, and do not indicate or imply that the device or element referred to must have a specific orientation, be constructed, operated or used in a specific orientation. Therefore, they should not be construed as limitations on the embodiments of this application.

[0026] In the description of the embodiments of this application, unless otherwise expressly specified and limited, technical terms such as "installation," "connection," "joining," and "fixing" should be interpreted broadly. For example, they can refer to a fixed connection, a detachable connection, or an integral part; they can refer to a mechanical connection or an electrical connection; they can refer to a direct connection or an indirect connection through an intermediate medium; they can refer to the internal communication of two components or the interaction between two components. Those skilled in the art can understand the specific meaning of the above terms in the embodiments of this application according to the specific circumstances.

[0027] In the description of the embodiments of this application, unless otherwise expressly specified and limited, the technical term "contact" should be interpreted broadly, and can be direct contact, contact through an intermediate medium layer, contact between two contacting parties with substantially no interaction force, or contact between two contacting parties with interaction force.

[0028] The following is a detailed description of this application.

[0029] Following cardiac surgery, a drainage tube is placed in the patient's pericardium or chest cavity to drain accumulated blood and effusion; this is an essential postoperative procedure. Currently, clinical practice places great emphasis on the patency of the drainage tube to accurately assess postoperative bleeding.

[0030] Drainage fluid usually remains liquid and does not coagulate naturally. However, when there is significant bleeding from the surgical wound after surgery, hemostatic drugs are often used clinically to control the bleeding. These drugs are a double-edged sword; while reducing wound bleeding, they also significantly increase the risk of thrombosis within the drainage tube. Once a thrombus forms, it can easily cause partial or complete blockage of the drainage tube.

[0031] This blockage can send doctors the false signal that bleeding has stopped, leading to a serious misjudgment of the actual amount of bleeding and preventing timely detection of ongoing postoperative active bleeding. Blood may thus continue to accumulate in the closed pericardial cavity until it causes acute cardiac tamponade, thus delaying the crucial window for timely open-chest hemostasis.

[0032] To address the aforementioned risks, the current feasible preventative measure is for healthcare workers to manually squeeze the drainage tube repeatedly to physically break up any newly formed blood clots and maintain the tube's patency. However, this method not only consumes a significant amount of the healthcare workers' time and energy, but its effectiveness is also unsustainable and cannot provide real-time relief.

[0033] To solve the above problems, refer to Figure 1 and Figure 2 This application provides a drainage device, which includes a drainage tube 1 and a sustained-release component 2. The drainage tube 1 has an internal end 11 and an external end 12. The internal end 11 is provided with a drainage port, and the external end 12 is provided with a connection port. The sustained-release component 2 includes a sustained-release element 21, which has a sustained-release cavity 211 for containing anticoagulants. The sustained-release cavity 211 is located inside the drainage tube 1 and is disposed close to the internal end 11 along the extension direction of the drainage tube 1 to release anticoagulants into the drainage tube 1.

[0034] The drainage tube 1 includes an internal end 11 and an external end 12. The internal end 11 is provided with a drainage port, and the external end 12 is provided with a connection port. This means that when the drainage device is in use, the internal end 11 is placed in a body cavity, incision, or interstitial space, and collects fluid (such as blood, exudate, etc.) through the drainage port. The external end 12 is placed outside the body, and guides the drained fluid to a collection container, such as a drainage bottle or drainage bag, through the connection port.

[0035] The sustained-release assembly 2 includes a sustained-release element 21 having a sustained-release cavity 211 for containing the anticoagulant. Here, the sustained-release element 21 is the core physical entity in the sustained-release assembly 2 for performing the "supplementary release" function, and the sustained-release element 21 has a hollow or porous structure forming the sustained-release cavity 211.

[0036] It should be noted that the sustained-release chamber 211 is not only used to contain the anticoagulant, but its structure and materials are also designed to control the release rate and power of the anticoagulant, enabling a slow and sustained release of the anticoagulant. For example, the sustained-release chamber 211 has an opening with a semi-permeable polymer membrane at the opening, through which the sustained-release chamber 211 releases the anticoagulant into the drainage tube 1; or, the chamber wall of the sustained-release chamber 211 has a microporous structure, through which the sustained-release chamber 211 releases the anticoagulant into the drainage tube 1.

[0037] In addition, anticoagulants can be selected from micro-heparin at a real-time anticoagulant concentration. Heparin is not only colorless but also present in trace amounts. After entering the drainage tube 1, it will not change the color or amount of the drainage fluid, which can better help to observe the drainage volume.

[0038] The fact that the sustained-release cavity 211 is located close to the inner end 11 along the extension direction of the drainage tube 1 means that the sustained-release cavity 211 is located closer to the end that extends into the body (i.e., the inner end 11) in the total length of the drainage tube 1, rather than in the middle or near the outer end (i.e., the outer end 12).

[0039] The drainage device provided in this application embodiment has an internal end 11 of the drainage tube 1 placed inside the body during use to collect fluid through the drainage port, and an external end 12 of the drainage tube 1 placed outside the body during use to guide the drained fluid to a collection container through a connection port. The internal end 11, as the source of the drainage tube 1, is also the location where thrombi are most likely to form. The sustained-release chamber 211 is located near the internal end 11, allowing anticoagulants to be provided as soon as the drainage fluid enters the very beginning of the drainage tube 1, maximally inhibiting the nucleation, growth, and spread of thrombi from the source. Because the hypercoagulability problem is solved at the drainage port, the fluid in the middle and later sections of the drainage tube (near the external end 12) can always remain in a hypocoagulable state, thereby ensuring the patency of the entire tubing from the internal end 11 to the external end 12.

[0040] Compared to the related technologies that maintain patency by squeezing the drainage tube 1 to break up the thrombus, the drainage device provided in this application includes a sustained-release element 21. The sustained-release chamber 211 of the sustained-release element 21 can release anticoagulants into the drainage tube 1 near the end 11 inside the body. This changes the approach from passive post-blockage treatment to proactive prevention from the source, reducing the probability of blockage in the drainage tube 1. It also reduces the effort and time required by medical staff and avoids misjudging the amount of postoperative bleeding, thus preventing the delay in timely thoracotomy and hemostasis.

[0041] In some embodiments of this application, the wall of the sustained-release chamber 211 is provided with a microneedle structure, through which the sustained-release chamber 211 releases anticoagulant into the drainage tube 1.

[0042] The wall of the sustained-release chamber 211 is provided with a microneedle structure. The sustained-release chamber 211 releases anticoagulant into the drainage tube 1 through the microneedle structure. This means that the wall of the sustained-release chamber 211 is integrated with a large number of microneedles. These microneedles can be a micro-needle array with a length of tens to hundreds of micrometers. The anticoagulant is directly delivered from inside the sustained-release chamber 211 to the space inside the drainage tube 1 through these microneedle channels.

[0043] Here, the sustained-release chamber 211 releases the anticoagulant into the drainage tube 1 through the microneedle structure. When the liquid flows in the drainage tube 1, a nearly static fluid boundary layer is formed around the sustained-release element 21, and the microneedle structure can directly penetrate this fluid boundary layer, allowing the anticoagulant to be released into the main fluid, greatly improving the utilization rate and onset speed of the anticoagulant.

[0044] Reference Figure 1 and Figure 2In some embodiments of this application, the sustained-release component 21 is a sustained-release tube, which includes a first segment 212 and a second segment 213. The first segment 212 is located inside the drainage tube 1, and the end of the first segment 212 facing the body end 11 is a blind end. The sustained-release cavity 211 is formed inside the first segment 212, and the second segment 213 is located outside the drainage tube 1. The sustained-release component 2 also includes a pumping component 3, which is connected to the second segment 213 for pumping anticoagulant into the sustained-release cavity 211.

[0045] The slow-release element 21 is a slow-release tube, meaning that the slow-release element 21 has a tubular structure.

[0046] The sustained-release tube comprises a first segment 212 and a second segment 213. The first segment 212 is located inside the drainage tube 1, with the end of the first segment 212 facing the body's internal end 11 being a blind end. The sustained-release cavity 211 is formed within the first segment 212, and the second segment 213 is located outside the drainage tube 1. This means the sustained-release tube is divided into two functional segments. The first segment 212 is located inside the drainage tube 1, and the sustained-release cavity 211 is formed within the first segment 212. The end of the first segment 212 facing the body's internal end 11 is closed, preventing the anticoagulant from flowing directly out of the end of the first segment 212. This avoids the anticoagulant flowing into the body through the drainage port of the drainage tube 1 under the action of the pump component 3, thus preventing adverse effects on the patient's surgical wound. The second segment 213 protrudes from a certain interface of the drainage tube 1, exposed outside the drainage tube 1, to connect with the pump component 3, allowing the pump component 3 to pump the anticoagulant into the sustained-release cavity 211.

[0047] Here, the sustained-release component 2 delivers anticoagulant to the sustained-release chamber 211 via the pump component 3, allowing medical staff to actively adjust the speed and dosage of the pump component 3 according to the patient's actual bleeding drainage situation. The dosage can be increased during periods of high coagulation risk and reduced or discontinued once the risk decreases, achieving truly individualized and precise treatment. Furthermore, the anticoagulant can be continuously replenished externally via the pump component 3, ensuring that the anticoagulant effect of the sustained-release component 21 is no longer limited by the initial drug load. Whether postoperative drainage needs to continue for one day or several days until the drainage tube is removed, an effective drug concentration can be guaranteed.

[0048] Of course, in some embodiments, the sustained-release element 21 may also be a block structure.

[0049] Reference Figure 1 and Figure 2 In some embodiments, a three-way valve 4 can also be provided between the second segment 213 and the pump fluid component 3 to control the drug delivery rate of the pump fluid component 3. For example, under normal circumstances, the drug delivery rate of the pump fluid component 3 can be controlled at 2 ml / h. Of course, it can also be self-controlled at any time according to the patient's drainage status, with a self-controlled rate of 0.5 ml / time and a self-controlled interval of 15 minutes. As the drug decreases, the dilation sac of the pump fluid component 3 will gradually shrink until it completely collapses, indicating that the drug has been used up.

[0050] Reference Figure 1 and Figure 2 In some embodiments of this application, the drainage device further includes a pressure monitoring module 5 and an alarm 6. The pressure monitoring module 5 is configured to monitor the pressure in the slow-release chamber 211. The alarm 6 is communicatively connected to the pressure monitoring module 5 and is configured to trigger an alarm when the pressure value monitored by the pressure monitoring module 5 exceeds the target range.

[0051] The pressure monitoring module 5 is configured to monitor the pressure inside the slow-release chamber 211, which means that the slow-release component 2 continuously measures and reads the pressure value inside the slow-release chamber 211 through the pressure monitoring module 5.

[0052] Alarm 6 is communicatively connected to pressure monitoring module 5 and is configured to trigger an alarm when the pressure value detected by pressure monitoring module 5 exceeds the target range. This means that the data acquired by pressure monitoring module 5 can be transmitted to alarm 6 in real time and accurately, and alarm 6 will trigger an alarm when the pressure value detected by pressure monitoring module 5 exceeds the target range. Here, the alarm signal of alarm 6 can be sound, light, or text / image prompts on an electronic screen.

[0053] Here, the sustained-release component 2 monitors the pressure within the sustained-release chamber 211 via the pressure monitoring module 5, enabling the alarm 6 to trigger when the pressure within the sustained-release chamber 211 exceeds the target range. Thus, when the pressure within the sustained-release chamber 211 rises due to blockage, medical staff can promptly obtain information about the situation through the alarm 6 and clean the sustained-release component 211 in a timely manner, ensuring its normal operation. Additionally, when the anticoagulant is about to run out, the pressure inside the sustained-release chamber 211 may change, potentially leading to an abnormal pressure drop. The alarm 6 can also warn of impending drug depletion, reminding medical staff to promptly add anticoagulant to the pump, ensuring the continuity of the anticoagulant effect and avoiding the potential risk of drainage tube blockage when there is no anticoagulant effect.

[0054] Reference Figure 1 and Figure 2 In some embodiments of this application, the first segment 212 includes a first part 2121 and a second part 2122, the radial dimension of the first part 2121 is larger than the radial dimension of the second part 2122, and the sustained-release cavity 211 is formed in the first part 2121.

[0055] The first segment 212 includes a first part 2121 and a second part 2122. The radial dimension of the first part 2121 is larger than that of the second part 2122. The sustained-release cavity 211 is formed within the first part 2121. This means that the first segment 212 is composed of two parts with different radial dimensions, and the sustained-release cavity 211 is located within the part with the larger radial dimension.

[0056] Here, the first segment 212 includes a first part 2121 and a second part 2122 with different radial dimensions. The sustained-release chamber 211 is located in the thickened first part 2121, which provides sufficient space for the drug reservoir, thereby loading anticoagulants for use for a sufficient period of time. At the same time, the second part 2122 maintains a standard size, ensuring the unobstructed main drainage channel and avoiding narrowing of the main drainage channel and increased drainage resistance caused by the built-in sustained-release element 21.

[0057] Of course, in some embodiments, the first segment 212 can also be set to a constant diameter.

[0058] Reference Figure 1 and Figure 2 In some embodiments of this application, the first segment 212 is coaxially arranged with the drainage tube 1.

[0059] The first segment 212 is coaxially positioned with the drainage tube 1. This means that the first segment 212 of the slow-release tube is precisely placed in the central channel of the drainage tube 1, with its axis aligned with the axis of the drainage tube 1.

[0060] Here, the first segment 212 is coaxially arranged with the drainage tube 1, so that a uniform annular flow channel is formed between the first segment 212 and the inner wall of the drainage tube 1. Liquid (blood, exudate, etc.) can flow smoothly and evenly from all sides with minimal flow resistance, thus improving drainage efficiency.

[0061] It should be noted that in the embodiment where the first segment 212 is coaxially arranged with the drainage tube 1, refer to Figure 1 The first segment 212 can be connected and fixed to the inner wall of the drainage tube 1 by the bracket 7. The bracket 7 can be integrally connected to the inner wall of the drainage tube 1, or it can be snapped into the inner wall of the drainage tube 1. This embodiment of the application does not limit this.

[0062] In addition, in an embodiment where the first segment 212 is coaxially arranged with the drainage tube 1 and the wall of the sustained-release cavity 211 is provided with a microneedle structure, the microneedle structure can be arranged around the circumference of the sustained-release cavity 211 so that the sustained-release cavity 211 can release anticoagulant at the same time; or, the microneedle structure can also be arranged on one or more sides of the sustained-release cavity 211 so that the sustained-release cavity 211 can release anticoagulant in a specific direction.

[0063] Reference Figure 3 In some embodiments of this application, the first segment 212 is disposed adjacent to the inner wall of the drainage tube 1.

[0064] The first segment 212 is set close to the inner wall of the drainage tube 1, which means that the first segment 212 of the slow-release tube is fixedly installed on the surface or close to the surface of the inner wall of the drainage tube 1.

[0065] Thrombus formation begins on the wall of drainage tube 1. Here, the first segment 212 is positioned immediately adjacent to the inner wall of drainage tube 1, allowing for the direct release of high-concentration anticoagulants at the initial stage of thrombus formation, achieving highly efficient local intervention with precise medication and direct effects. Furthermore, compared to a design where the first segment 212 is coaxially aligned with drainage tube 1, this placement adjacent to the inner wall of drainage tube 1 maximizes the preservation of the central flow area, ensuring smooth passage of drainage fluid (blood, exudate, etc.) and minimizing the risk of blockage.

[0066] It should be noted that in the embodiment where the first segment 212 is disposed adjacent to the inner wall of the drainage tube 1, the tube wall of the first segment 212 can be integrally connected with the inner wall of the drainage tube 1 to form a double-lumen tube structure; or, the tube wall of the first segment 212 can also be bonded and fixed to the inner wall of the drainage tube 1. In this respect, the embodiments of this application do not limit it.

[0067] In addition, in an embodiment where the first segment 212 is disposed adjacent to the inner wall of the drainage tube 1 and the wall of the sustained-release cavity 211 is provided with a microneedle structure, the microneedle structure can be disposed away from the side of the sustained-release cavity 211 adjacent to the drainage tube 1.

[0068] In some embodiments of this application, the ratio between the radial dimension of the drainage tube 1 and the radial dimension of the slow-release tube is greater than 12 and less than 28.

[0069] The ratio between the radial dimension of drainage tube 1 and the radial dimension of the sustained-release tube is greater than 12 and less than 28, which is a designed and experimentally verified golden ratio range that can achieve the best drainage effect. Within the above ratio range, there are several possibilities for the selection of the radial dimensions of drainage tube 1 and sustained-release tube. For example, the radial dimension of drainage tube 1 can be in the range of 10mm-11mm, and the radial dimension of sustained-release tube can be in the range of 0.4mm-0.8mm.

[0070] Here, if the ratio between the radial dimension of drainage tube 1 and the radial dimension of the sustained-release tube is too small (≤12), it means the sustained-release tube is too thick, which will severely encroach on the effective flow area of ​​drainage tube 1, leading to increased drainage resistance, poor drainage, and thus easily causing physical blockage. If the ratio between the radial dimension of drainage tube 1 and the radial dimension of the sustained-release tube is too large (≥28), it means the sustained-release tube is too thin or drainage tube 1 is too thick. In this case, the anticoagulant released from the sustained-release tube needs to diffuse a long distance to reach the central area of ​​drainage tube 1, and the drainage fluid in the center may not receive an effective concentration of drug, resulting in poor anticoagulant effect. Therefore, a ratio between the radial dimension of drainage tube 1 and the radial dimension of the sustained-release tube greater than 12 and less than 28 can reduce the probability of blockage while ensuring that the anticoagulant can be quickly and evenly dispersed throughout the drainage fluid flow, ensuring the anticoagulant effect.

[0071] In some embodiments of this application, the inner end 11 is provided with a cushioning pad.

[0072] The inner end 11 is the foremost part of the guide tube 1 that first enters the body cavity. A cushioning pad is provided at this end, which can be made of a biocompatible soft material such as medical-grade silicone, foamed polymer, or hydrogel. The cushioning pad can be a smooth, cap-like structure wrapped around the end of the tube, or it can be a soft wing attached to the side.

[0073] Following cardiac surgery, the internal end 11 may be in prolonged contact with tissues such as the heart and major blood vessels. Compression from the rigid tube end could lead to accidental damage to local tissues. Here, the internal end 11 is equipped with a cushioning pad, which can distribute pressure and fundamentally eliminate this potential risk of compression.

[0074] In addition, the buffer pad can be made of a material with strong absorbency to absorb the drainage fluid.

[0075] In some embodiments of this application, the drainage tube 1 has graduations on its wall.

[0076] The drainage tube 1 has graduations on its wall, which means that a series of equally spaced, numbered markings are printed or engraved on the outer surface of the part of the drainage tube 1 that extends into the patient's body.

[0077] During the catheter placement procedure, medical staff can see the depth of the drainage tube 1 inside the body in real time and intuitively. In this way, the internal end 11 can be accurately placed in the target position according to the needs of the surgery, avoiding the problem of placement too shallow or too deep, and improving the accuracy and standardization of the surgery.

[0078] The above description is merely a specific embodiment of this application, enabling those skilled in the art to understand or implement this application. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the general principles defined herein may be implemented in other embodiments without departing from the spirit or scope of this application. Therefore, this application is not to be limited to the embodiments described herein, but is to be accorded the widest scope consistent with the principles and novel features disclosed herein.

Claims

1. A drainage device, characterized in that, include: A drainage tube having an internal end and an external end, the internal end having a drainage port and the external end having a connection port; A sustained-release assembly, the sustained-release assembly including a sustained-release element having a sustained-release cavity for containing an anticoagulant, the sustained-release cavity being located within the drainage tube along the extension direction of the drainage tube, the sustained-release cavity being disposed near the inner end of the body for releasing the anticoagulant into the drainage tube.

2. The drainage device according to claim 1, characterized in that, The wall of the sustained-release chamber is provided with a microneedle structure, through which the sustained-release chamber releases anticoagulant into the drainage tube.

3. The drainage device according to claim 1, characterized in that, The sustained-release component is a sustained-release tube, which includes a first section and a second section. The first section is located inside the drainage tube, and the end of the first section facing the body is a blind end. The sustained-release cavity is formed inside the first section, and the second section is located outside the drainage tube. The sustained-release assembly also includes a pumping component connected to the second section for pumping anticoagulant into the sustained-release cavity.

4. The drainage device according to claim 3, characterized in that, The drainage device also includes a pressure monitoring module and an alarm. The pressure monitoring module is configured to monitor the pressure in the slow-release chamber. The alarm is communicatively connected to the pressure monitoring module and is configured to trigger an alarm when the pressure value monitored by the pressure monitoring module exceeds the target range.

5. The drainage device according to claim 3, characterized in that, The first segment includes a first part and a second part, wherein the radial dimension of the first part is greater than the radial dimension of the second part, and the sustained-release cavity is formed within the first part.

6. The drainage device according to any one of claims 3-5, characterized in that, The first segment is coaxially arranged with the drainage tube.

7. The drainage device according to any one of claims 3-5, characterized in that, The first segment is located immediately adjacent to the inner wall of the drainage tube.

8. The drainage device according to any one of claims 3-5, characterized in that, The ratio between the radial dimension of the drainage tube and the radial dimension of the slow-release tube is greater than 12 and less than 28.

9. The drainage device according to any one of claims 1-5, characterized in that, The inner end of the body is provided with a cushioning pad.

10. The drainage device according to any one of claims 1-5, characterized in that, The drainage tube has graduations on its wall.

Images